S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)
S&P 500   4,604.37 (+0.41%)
DOW   36,247.87 (+0.36%)
QQQ   392.17 (+0.45%)
AAPL   195.71 (+0.74%)
MSFT   374.23 (+0.88%)
META   332.75 (+1.89%)
GOOGL   134.99 (-1.42%)
AMZN   147.42 (+0.37%)
TSLA   243.84 (+0.49%)
NVDA   475.06 (+1.95%)
NIO   7.38 (-1.47%)
BABA   72.14 (-0.26%)
AMD   128.92 (+0.43%)
T   16.92 (-0.99%)
F   11.01 (+1.76%)
MU   74.96 (+1.78%)
CGC   0.80 (+10.74%)
GE   120.59 (+0.93%)
DIS   92.82 (+0.51%)
AMC   6.93 (+1.61%)
PFE   28.78 (+0.52%)
PYPL   58.94 (+0.79%)
XOM   99.55 (+1.15%)

ResMed Stock Price, News & Analysis (NYSE:RMD)

$162.87
-0.62 (-0.38%)
(As of 04:37 PM ET)
Compare
Today's Range
$162.48
▼
$163.93
50-Day Range
$134.74
▼
$164.00
52-Week Range
$132.24
▼
$243.52
Volume
756,568 shs
Average Volume
992,527 shs
Market Capitalization
$23.96 billion
P/E Ratio
26.44
Dividend Yield
1.18%
Price Target
$202.33
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
24.0% Upside
$202.33 Price Target
Short Interest
Healthy
4.29% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.56
Upright™ Environmental Score
News Sentiment
1.23mentions of ResMed in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$2.96 M Sold Last Quarter
Proj. Earnings Growth
9.73%
From $7.30 to $8.01 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.28 out of 5 stars

Medical Sector

13th out of 960 stocks

Medical Instruments & Supplies Industry

1st out of 8 stocks

See Top Rated MarketRank™ Stocks Here

RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

December 6, 2023 | americanbankingnews.com
ResMed Inc. (NYSE:RMD) Given Consensus Recommendation of "Moderate Buy" by Analysts
December 4, 2023 | americanbankingnews.com
Q2 2024 EPS Estimates for ResMed Inc. (NYSE:RMD) Raised by Analyst
December 8, 2023 | Edge On The Street (Ad)
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
December 1, 2023 | americanbankingnews.com
Brett Sandercock Sells 3,000 Shares of ResMed Inc. (NYSE:RMD) Stock
November 30, 2023 | finance.yahoo.com
Insider Sell: CFO Brett Sandercock Sells 3,000 Shares of ResMed Inc (RMD)
November 24, 2023 | msn.com
ResMed issues urgent safety notice over magnetic CPAP masks
November 23, 2023 | afr.com
This fundie is betting against the ResMed sceptics
November 10, 2023 | finance.yahoo.com
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
December 8, 2023 | Edge On The Street (Ad)
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?
A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.
November 7, 2023 | finance.yahoo.com
ResMed Inc's Dividend Analysis
November 6, 2023 | fool.com.au
Want to receive the ResMed dividend? You'll need to be quick!
November 6, 2023 | msn.com
ASX Large Caps: CSL, Resmed, and Westpac led gainers; data shows Aussie economy is softening
November 3, 2023 | finance.yahoo.com
Be Sure To Check Out ResMed Inc. (NYSE:RMD) Before It Goes Ex-Dividend
October 31, 2023 | fool.com.au
ResMed share price is 'oversold' with huge upside: Citi
October 30, 2023 | seekingalpha.com
ResMed: Down 60% With Tremendous Long-Term Potential
October 28, 2023 | markets.businessinsider.com
Analysts Conflicted on These Healthcare Names: Resmed (RMD) and MiMedx Group (MDXG)
October 27, 2023 | seekingalpha.com
ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
October 26, 2023 | fool.com.au
ResMed share price falls despite Q1 earnings beat
October 26, 2023 | msn.com
ResMed's higher costs dull quarterly sales rise, shares fall
October 26, 2023 | finance.yahoo.com
ResMed (RMD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
October 26, 2023 | finance.yahoo.com
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
October 18, 2023 | msn.com
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
October 17, 2023 | fool.com.au
Resmed shares are at an 'attractive valuation' and could be a 'great buying opportunity': fund manager
October 17, 2023 | msn.com
Oppenheimer Maintains Resmed (RMD) Outperform Recommendation
October 12, 2023 | in.investing.com
ResMed minimal EPS growth limits a near-term re-rating - RBC Capital
October 10, 2023 | fool.com.au
The Resmed share price collapse is a buying opportunity according to this broker
October 2, 2023 | forbes.com
Will ResMed Stock Rebound To Its Pre-Inflation Shock Highs Of $300?
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/21 Dividend
8/16/2023
Dividend Payable
9/21/2023
Last Earnings
10/26/2023
Ex-Dividend for 12/14 Dividend
11/08/2023
Today
12/08/2023
Dividend Payable
12/14/2023
Next Earnings (Estimated)
1/25/2024
Fiscal Year End
6/30/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Medical Instruments & Supplies
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NYSE:RMD
CUSIP
76115210
CIK
943819
Web
www.resmed.com
Phone
(858) 836-5000
Fax
858-836-5501
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$202.33
High Stock Price Target
$290.00
Low Stock Price Target
$160.00
Potential Upside/Downside
+24.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$6.16
Trailing P/E Ratio
26.40
Forward P/E Ratio
22.28
P/E Growth
2.73
Net Income
$897.56 million
Net Margins
20.72%
Pretax Margin
25.42%
Return on Equity
24.14%
Return on Assets
14.42%

Debt

Debt-to-Equity Ratio
0.32
Current Ratio
2.99
Quick Ratio
1.75

Sales & Book Value

Annual Sales
$4.38 billion
Price / Sales
5.47
Cash Flow
$7.96 per share
Price / Cash Flow
20.44
Book Value
$28.11 per share
Price / Book
5.79

Miscellaneous

Outstanding Shares
147,092,000
Free Float
145,312,000
Market Cap
$23.92 billion
Optionable
Optionable
Beta
0.55

Social Links

20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ResMed was last updated on Tuesday, November 28, 2023 at 9:50 PM.

Pros

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. This positions the company in a growing industry with high demand for healthcare solutions.
  • The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. This diversification allows ResMed Inc. to capture revenue from multiple sources and mitigate risks.
  • ResMed Inc. offers various products and solutions for a range of respiratory disorders, including ventilation devices, diagnostic products, mask systems, and dental devices. This wide product portfolio caters to different patient needs and provides potential for revenue growth.
  • The company provides cloud-based software informatics solutions to manage patient outcomes. This technology-driven approach enhances patient care and can lead to improved patient outcomes, which may attract more customers and increase market share.
  • ResMed Inc. has a strong distribution network, selling its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. This established distribution network provides a competitive advantage and facilitates market penetration.

Cons

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • ResMed Inc. operates in a highly competitive industry. The healthcare equipment market is crowded with numerous players, which may result in pricing pressures and reduced profit margins.
  • The company's success is dependent on its ability to develop and introduce innovative products and solutions. Failure to keep up with technological advancements or meet customer demands could lead to loss of market share and revenue decline.
  • ResMed Inc. faces regulatory risks, as the healthcare industry is subject to strict regulations and compliance requirements. Changes in regulations or non-compliance could impact the company's operations and financial performance.
  • The stock price of ResMed Inc. is subject to market volatility and can be influenced by various factors, such as economic conditions, industry trends, and investor sentiment. Investors should carefully consider the risks associated with investing in the stock market.
  • Investors should conduct thorough research and analysis before making investment decisions. It is important to consider factors such as the company's financial health, competitive position, and growth prospects to make informed investment choices.














RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings or view top-rated stocks.

What is ResMed's stock price target for 2024?

12 brokerages have issued 12-month target prices for ResMed's shares. Their RMD share price targets range from $160.00 to $290.00. On average, they anticipate the company's stock price to reach $202.33 in the next year. This suggests a possible upside of 24.0% from the stock's current price.
View analysts price targets for RMD or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2023?

ResMed's stock was trading at $208.13 on January 1st, 2023. Since then, RMD shares have decreased by 21.6% and is now trading at $163.17.
View the best growth stocks for 2023 here.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 5,720,000 shares, an increase of 18.4% from the October 15th total of 4,830,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the short-interest ratio is currently 3.3 days.
View ResMed's Short Interest.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, January 25th 2024.
View our RMD earnings forecast.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its quarterly earnings results on Thursday, October, 26th. The medical equipment provider reported $1.64 earnings per share for the quarter, beating the consensus estimate of $1.63 by $0.01. The medical equipment provider earned $1.10 billion during the quarter, compared to the consensus estimate of $1.10 billion. ResMed had a trailing twelve-month return on equity of 24.14% and a net margin of 20.72%. The business's quarterly revenue was up 16.0% on a year-over-year basis. During the same period last year, the business earned $1.51 EPS.
Read the conference call transcript.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Thursday, October 26th. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.48 per share on Thursday, December 14th. This represents a $1.92 annualized dividend and a yield of 1.18%. The ex-dividend date is Wednesday, November 8th.
Read our dividend analysis for RMD.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.20%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.97% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What ETFs hold ResMed's stock?

ETFs with the largest weight of ResMed (NYSE:RMD) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Motley Fool Mid-Cap Growth ETF (TMFM), Fidelity Digital Health ETF (FDHT), Emerge EMPWR Sustainable Select Growth Equity ETF (EMGC), iShares U.S. Medical Devices ETF (IHI), Simplify Market Neutral Equity Long/Short ETF (EQLS), First Trust Indxx Medical Devices ETF (MDEV) and Capital Group Global Growth Equity ETF (CGGO).

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (2.59%), Morgan Stanley (1.58%), Invesco Ltd. (1.36%), Northern Trust Corp (1.01%), Bank of New York Mellon Corp (0.77%) and Legal & General Group Plc (0.68%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -